Compass Therapeutics (CMPX) Non-Current Debt (2019 - 2020)
Compass Therapeutics (CMPX) reported Non-Current Debt of $1.9 million for Q4 2020, down 79.91% on a YoY basis from $9.3 million in Q1 2020, and down 49.95% sequentially from $3.7 million in Q3 2020.
Compass Therapeutics (CMPX) Non-Current Debt (2019 - 2020) Analysis & Trends
Compass Therapeutics (CMPX) has 2 years of Non-Current Debt data on file, last reported at $1.9 million in Q4 2020.
- For the quarter ending Q4 2020, Non-Current Debt fell 79.91% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2020 stood at $1.9 million (down 79.91% YoY), and the FY2020 full-year result was $1.9 million, down 79.91% from the prior year.
- Non-Current Debt declined to $1.9 million in Q4 2020, from $3.7 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $9.3 million in Q4 2019 to a low of $1.9 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Compass Therapeutics | 395.17 Mn | 200.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 1.87 Mn |
| Sep 30, 2020 | 3.73 Mn |
| Jun 30, 2020 | 5.59 Mn |
| Dec 31, 2019 | 9.29 Mn |